Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventric...

Descripció completa

Dades bibliogràfiques
Autors principals:	Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko
Format:	Article
Idioma:	Russian
Publicat:	"Consilium Medicum" Publishing house 2015-09-01
Col·lecció:	Терапевтический архив
Matèries:	aldosterone mineralocorticoid receptor antagonists chronic heart failure
Accés en línia:	https://ter-arkhiv.ru/0040-3660/article/view/31823

Ítems similars

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
per: S N Tereshchenko, et al.
Publicat: (2013-12-01)

Heart failure: the role for mineralocorticoid receptor antagonists
per: Bertram Pitt
Publicat: (2014-05-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
per: Natalia V. Safronova, et al.
Publicat: (2022-01-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
per: A. M. Esayan, et al.
Publicat: (2018-04-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
per: Josefin Henrysson, et al.
Publicat: (2023-02-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
per: Daiji Kawanami, et al.
Publicat: (2021-10-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
per: MG Bubnova
Publicat: (2014-12-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
per: Yuta Tezuka, et al.
Publicat: (2021-03-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
per: Mary Elizabeth Moss, et al.
Publicat: (2015-09-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
per: Pascal R. D. Clephas, et al.
Publicat: (2023-04-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
per: Arga Setyo Adji, et al.
Publicat: (2024-11-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
per: Shuhui Zhai, et al.
Publicat: (2024-09-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
per: Irina N. Bobkova
Publicat: (2023-11-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
per: Memory MUKANGWA, et al.
Publicat: (2019-12-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
per: O. A. Osipova, et al.
Publicat: (2021-11-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
per: N. A. Nuritdinov, et al.
Publicat: (2020-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
per: Houry Puzantian, et al.
Publicat: (2024-12-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
per: Chang Geng, et al.
Publicat: (2023-11-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
per: Kisho Miyasako, et al.
Publicat: (2024-12-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
per: Luo Shi, et al.
Publicat: (2019-11-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
per: Ulrich Kintscher, et al.
Publicat: (2023-06-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
per: Nappi J, et al.
Publicat: (2011-06-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
per: Chien‐Wei Huang, et al.
Publicat: (2025-02-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
per: A. G. Evdokimova, et al.
Publicat: (2023-01-01)

Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease
per: Andrei Niculae, et al.
Publicat: (2022-03-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
per: Nina Vodošek Hojs, et al.
Publicat: (2021-06-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
per: Irene Lucía Ennis, et al.
Publicat: (2021-01-01)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
per: Greg H. Tesch, et al.
Publicat: (2017-05-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
per: S. R. Gilyarevsky, et al.
Publicat: (2023-10-01)

Heart failure as a complication of myocardial infarction: rational therapy. Case report
per: Igor V. Zhirov, et al.
Publicat: (2022-12-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
per: Dong-Lim Kim, et al.
Publicat: (2023-02-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
per: Stephen eOrena, et al.
Publicat: (2013-10-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
per: Marie Pieronne‐Deperrois, et al.
Publicat: (2021-06-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
per: Sofia S. Pereira, et al.
Publicat: (2021-04-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
per: Giuseppe eMaiolino, et al.
Publicat: (2015-02-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
per: Ana Sanhueza, et al.
Publicat: (2020-09-01)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
per: Camila Q. Felipe, et al.
Publicat: (2022-06-01)

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
per: Mai Rosenberg, et al.
Publicat: (2024-09-01)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
per: Argen Mamazhakypov, et al.
Publicat: (2023-01-01)

Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta‐Analysis, and Meta‐Regression to Identify Modifying Factors
per: Joachim Alexandre, et al.
Publicat: (2019-11-01)